术前预测肝细胞癌微血管侵犯的研究进展

周晓涵; 台蕴泽; 周娟

doi:10.12354/j.issn.1000-8179.2022.20210746

术前预测肝细胞癌微血管侵犯的研究进展

doi: 10.12354/j.issn.1000-8179.2022.20210746

周晓涵^1,,
台蕴泽¹,
周娟^2, ,

1.
四川大学华西临床医学院（成都市 610041）
2.
四川大学华西医院实验医学科

基金项目: 本文课题受四川省科技计划项目 (编号：2020YJ0106) 资助

详细信息

作者简介:
周晓涵：专业方向为检验医学

通讯作者:
周娟　zhoujuan39@qq.com

计量
- 文章访问数: 383
- HTML全文浏览量: 99
- PDF下载量: 76
- 被引次数: 0
出版历程
- 收稿日期: 2021-05-12
- 网络出版日期: 2022-02-11

Research progress on the preoperative prediction of microvascular invasion in hepatocellular carcinoma

Xiaohan Zhou^1
,,
Yunze Tai¹,
Juan Zhou^{2
, ,}

1.
West China School of Medicine, Sichuan University, Chengdu 610041, China
2.
Department of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu 610041, China

Funds: This work was supported by Science and Technology Plan Project of Sichuan Province (No.2020YJ0106)

More Information

Corresponding author: Juan Zhou; E-mail: zhoujuan39@qq.com

摘要

摘要: 肝细胞癌（hepatocellular carcinoma，HCC）防治是世界范围内的重要公共卫生问题，目前，手术是HCC治疗的主要方式，而复发转移是提高HCC患者生存率的主要障碍。微血管侵犯(microvascular invasion, MVI)是肝血管内微转移的癌细胞栓子，与HCC术后复发转移及不良预后密切相关。目前MVI仅能通过术后病理检查确认，而术前预测MVI有助于HCC患者的精准治疗、提高患者生存率及筛选最佳肝移植受者。本文强调了术前预测MVI对HCC患者精准治疗的重要性，总结了影像学特征、常规血清蛋白标志物、新型分子标志物在预测MVI中的最新进展，以及多指标联合模型对MVI的预测能力，并评估了液体活检在MVI预测方面的巨大潜力。
- 微血管侵犯 /
- 新型分子标志物 /
- 多指标联合预测模型 /
- 液体活检
Abstract: The prevention and treatment of hepatocellular carcinoma (HCC) is a major public health problem worldwide. At present, surgery is the main treatment method for HCC, while recurrence and metastasis are the main obstacles to the improvement of the survival rate of HCC patients. Microvascular invasion (MVI) is the embolus of cancer cells with micro-metastasis in liver vessels, which is closely associated with the postoperative recurrence, metastasis, and poor prognosis of HCC. At present, MVI can only be confirmed through postoperative pathological examination, while the preoperative prediction of MVI is helpful for the accurate treatment of HCC patients and helps further improve the survival rate of patients and select the best liver transplantation recipients. This review emphasizes the importance of the preoperative prediction of MVI for accurate treatment of HCC patients, summarizes the latest advances in the prediction of MVI by imaging features, routine serum protein markers, and novel molecular markers, highlights the MVI prediction ability of the multi-index prediction model, and evaluates the great potential of liquid biopsy in predicting MVI.
- microvascular invasion (MVI) /
- novel molecular marker /
- multi-index prediction model /
- liquid biopsy

HTML全文

参考文献(47)

[1]	Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3):209-249. doi: 10.3322/caac.21660
[2]	Kobayashi T, Aikata H, Kobayashi T, et al. Patients with early recurrence of hepatocellular carcinoma have poor prognosis[J]. Hepatobiliary Pancreat Dis Int, 2017, 16(3):279-288. doi: 10.1016/S1499-3872(16)60181-9
[3]	Erstad DJ, Tanabe KK. Prognostic and therapeutic implications of microvascular invasion in hepatocellular carcinoma[J]. Ann Surg Oncol, 2019, 26(5):1474-1493.
[4]	中华人民共和国国家卫生健康委员会医政医管局.原发性肝癌诊疗规范(2019年版)[J].中国临床医学,2020,27(1):140-160.
[5]	Rodríguez-Perálvarez M, Luong TV, Andreana L, et al. A systematic review of microvascular invasion in hepatocellular carcinoma: diagnostic and prognostic variability[J]. Ann Surg Oncol, 2013, 20(1):325-339.
[6]	Yamashita YI, Imai K, Yusa T, et al. Microvascular invasion of single small hepatocellular carcinoma ≤3 cm: Predictors and optimal treatments[J]. Ann Gastroenterol Surg, 2018, 2(3):197-203. doi: 10.1002/ags3.12057
[7]	Feng LH, Dong H, Lau WY, et al. Novel microvascular invasion-based prognostic nomograms to predict survival outcomes in patients after R0 resection for hepatocellular carcinoma[J]. J Cancer Res Clin Oncol, 2017, 143(2):293-303. doi: 10.1007/s00432-016-2286-1
[8]	Chen ZH, Zhang XP, Wang H, et al. Effect of microvascular invasion on the postoperative long-term prognosis of solitary small HCC: a systematic review and meta-analysis[J]. HPB (Oxford), 2019, 21(8):935-944. doi: 10.1016/j.hpb.2019.02.003
[9]	Jiao S, Li G, Zhang D, et al. Anatomic versus non-anatomic resection for hepatocellular carcinoma, do we have an answer? A meta-analysis[J]. Int J Surg, 2020, 80:243-255. doi: 10.1016/j.ijsu.2020.05.008
[10]	雷正清. 早期肝癌微血管侵犯的术前预测和对肝切除术切缘选择的影响[D]. 第二军医大学, 2016.
[11]	Chen K, Xia Y, Wang H, et al. Adjuvant iodine-125 brachytherapy for hepatocellular carcinoma after complete hepatectomy: a randomized controlled trial[J]. PLoS One, 2013, 8(2):e57397. doi: 10.1371/journal.pone.0057397
[12]	Peter RG, Alejandro F, Josep ML, et al. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma[J]. J Hepatol, 2018, 69(1):182-236. doi: 10.1016/j.jhep.2018.03.019
[13]	Lee S, Kang TW, Song KD, et al. Effect of microvascular invasion risk on early recurrence of hepatocellular carcinoma after surgery and radiofrequency ablation[J]. Ann Surg, 2021, 273(3):564-571. doi: 10.1097/SLA.0000000000003268
[14]	Pavel MC, Fuster J. Expansion of the hepatocellular carcinoma Milan criteria in liver transplantation: future directions[J]. World J Gastroenterol, 2018, 24(32):3626-3636. doi: 10.3748/wjg.v24.i32.3626
[15]	Vitale A, Cucchetti A, Qiao GL, et al. Is resectable hepatocellular carcinoma a contraindication to liver transplantation? a novel decision model based on "number of patients needed to transplant" as measure of transplant benefit[J]. J Hepatol, 2014, 60(6):1165-1171. doi: 10.1016/j.jhep.2014.01.022
[16]	Song L, Li J, Luo Y. The importance of a nonsmooth tumor margin and incomplete tumor capsule in predicting HCC microvascular invasion on preoperative imaging examination: a systematic review and meta-analysis[J]. Clin Imaging, 2020, 76:77-82.
[17]	Cao L, Chen J, Duan T, et al. Diffusion kurtosis imaging (DKI) of hepatocellular carcinoma: correlation with microvascular invasion and histologic grade[J]. Quant Imaging Med Surg, 2019, 9(4):590-602. doi: 10.21037/qims.2019.02.14
[18]	Zhu YJ, Feng B, Wang S, et al. Model-based three-dimensional texture analysis of contrast-enhanced magnetic resonance imaging as a potential tool for preoperative prediction of microvascular invasion in hepatocellular carcinoma[J]. Oncol Lett, 2019, 18(1):720-732.
[19]	Sabaté-Llobera A, Mestres-Martí J, Reynés-Llompart G, et al. 2-[¹⁸F]FDG PET/CT as a predictor of microvascular invasion and high histological grade in patients with hepatocellular carcinoma[J]. Cancers (Basel), 2021, DOI: 10.3390/CANCERS13112554.
[20]	Zhao H, Hua Y, Lu Z, et al. Prognostic value and preoperative predictors of microvascular invasion in solitary hepatocellular carcinoma ≤ 5 cm without macrovascular invasion[J]. Oncotarget, 2017, 8(37):61203-61214. doi: 10.18632/oncotarget.18049
[21]	Ma XL, Zhu J, Wu J, et al. Significance of PIVKA-II levels for predicting microvascular invasion and tumor cell proliferation in Chinese patients with hepatitis B virus-associated hepatocellular carcinoma[J]. Oncol Lett, 2018, 15(6):8396-8404.
[22]	Ding GY, Zhu XD, Ji Y, et al. Serum PON1 as a biomarker for the estimation of microvascular invasion in hepatocellular carcinoma[J]. Ann Transl Med, 2020, 8(5):204. doi: 10.21037/atm.2020.01.44
[23]	Liu M, Wang L, Zhu H, et al. A preoperative measurement of serum microRNA-125b may predict the presence of microvascular invasion in hepatocellular carcinomas patients[J]. Transl Oncol, 2016, 9(3):167-172. doi: 10.1016/j.tranon.2016.03.002
[24]	Psaila B, Lyden D. The metastatic niche: adapting the foreign soil[J]. Nat Rev Cancer, 2009, 9(4):285-293. doi: 10.1038/nrc2621
[25]	Zhang T, Ding G, Wang H, et al. miR-497 targets VEGF signal pathway to regulate proliferation, invasion and migration of hepatocellular carcinoma cells: a primary study using DEC-MRI[J]. J buon, 2021, 26(2):418-428.
[26]	Lu J, Li B, Xiong X, et al. RNA sequencing reveals the long noncoding RNA and mRNA profiles and identifies long non-coding RNA TSPAN12 as a potential microvascular invasion-related biomarker in hepatocellular carcinoma[J]. Biomed Pharmacother, 2020, 126:110111.
[27]	Wang P, Xu LL, Zheng XB, et al. Correlation between the expressions of circular RNAs in peripheral venous blood and clinicopathological features in hepatocellular carcinoma[J]. Ann Transl Med, 2020, 8(6):338. doi: 10.21037/atm.2020.02.134
[28]	Deng G, Yao L, Zeng F, et al. Nomogram for preoperative prediction of microvascular invasion risk in hepatocellular carcinoma[J]. Cancer Manag Res, 2019, 11:9037-9045. doi: 10.2147/CMAR.S216178
[29]	赵晖. 肝细胞癌微血管侵犯的预后评估及术前预测模型的建立[D]. 南京医科大学, 2018.
[30]	Yao Z, Dong Y, Wu G, et al. Preoperative diagnosis and prediction of hepatocellular carcinoma: Radiomics analysis based on multi-modal ultrasound images[J]. BMC Cancer, 2018, 18(1):1089. doi: 10.1186/s12885-018-5003-4
[31]	Jiang YQ, Cao SE, Cao S, et al. Preoperative identification of microvascular invasion in hepatocellular carcinoma by XGBoost and deep learning[J]. J Cancer Res Clin Oncol, 2021, 147(3):821-833. doi: 10.1007/s00432-020-03366-9
[32]	Liu J, Dang H, Wang XW. The significance of intertumor and intratumor heterogeneity in liver cancer[J]. Exp Mol Med, 2018, 50(1):e416.
[33]	Li X, Wang H, Li T, et al. Circulating tumor DNA/circulating tumor cells and the applicability in different causes induced hepatocellular carcinoma[J]. Curr Probl Cancer, 2020, 44(2):100516. doi: 10.1016/j.currproblcancer.2019.100516
[34]	Cai H, Zhang Y, Zhang H, et al. Prognostic role of tumor mutation burden in hepatocellular carcinoma after radical hepatectomy[J]. J Surg Oncol, 2020, 121(6):1007-1014. doi: 10.1002/jso.25859
[35]	Wang J, Huang A, Wang YP, et al. Circulating tumor DNA correlates with microvascular invasion and predicts tumor recurrence of hepatocellular carcinoma[J]. Ann Transl Med, 2020, 8(5):237. doi: 10.21037/atm.2019.12.154
[36]	Rothwell DG, Ayub M, Cook N, et al. Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study[J]. Nat Med, 2019, 25(5):738-743. doi: 10.1038/s41591-019-0380-z
[37]	Wang D, Xu Y, Goldstein JB, et al. Preoperative evaluation of microvascular invasion with circulating tumour DNA in operable hepatocellular carcinoma[J]. Liver Int, 2020, 40(8):1997-2007. doi: 10.1111/liv.14463
[38]	Zhou J, Zhang Z, Zhou H, et al. Preoperative circulating tumor cells to predict microvascular invasion and dynamical detection indicate the prognosis of hepatocellular carcinoma[J]. BMC Cancer, 2020, 20(1):1047. doi: 10.1186/s12885-020-07488-8
[39]	He YZ, He K, Huang RQ, et al. Preoperative evaluation and prediction of clinical scores for hepatocellular carcinoma microvascular invasion: a single-center retrospective analysis[J]. Ann Hepatol, 2020, 19(6):654-661. doi: 10.1016/j.aohep.2020.07.002
[40]	Okajima W, Komatsu S, Ichikawa D, et al. Liquid biopsy in patients with hepatocellular carcinoma: Circulating tumor cells and cell-free nucleic acids[J]. World J Gastroenterol, 2017, 23(31):5650-5668. doi: 10.3748/wjg.v23.i31.5650
[41]	Ruivo CF, Adem B, Silva M, et al. The biology of cancer exosomes: insights and new perspectives[J]. Cancer Res, 2017, 77(23):6480-6488.
[42]	Chen L, Guo P, He Y, et al. HCC-derived exosomes elicit HCC progression and recurrence by epithelial-mesenchymal transition through MAPK/ERK signalling pathway[J]. Cell Death Dis, 2018, 9(5):513. doi: 10.1038/s41419-018-0534-9
[43]	Li R, Wang Y, Zhang X, et al. Exosome-mediated secretion of LOXL4 promotes hepatocellular carcinoma cell invasion and metastasis[J]. Mol Cancer, 2019, 18(1):18.
[44]	Xie Z, Zhou F, Yang Y, et al. Lnc-PCDH9-13: 1 is a hypersensitive and specific biomarker for early hepatocellular carcinoma[J]. EBioMedicine, 2018, 33:57-67. doi: 10.1016/j.ebiom.2018.06.026
[45]	Hann HW, Jain S, Park G, et al. Detection of urine DNA markers for monitoring recurrent hepatocellular carcinoma[J]. Hepatoma Res, 2017, 3:105-111. doi: 10.20517/2394-5079.2017.15
[46]	Hu HT, Wang Z, Kuang M, et al. Need for normalization: the non-standard reference standard for microvascular invasion diagnosis in hepatocellular carcinoma[J]. World J Surg Oncol, 2018, 16(1):50. doi: 10.1186/s12957-018-1347-0
[47]	Cong WM, Bu H, Chen J, et al. Practice guidelines for the pathological diagnosis of primary liver cancer: 2015 update[J]. World J Gastroenterol, 2016, 22(42):9279-9287. doi: 10.3748/wjg.v22.i42.9279